Novel vaccines targeting dendritic cells by coupling allergoids to mannan

Allergen-specific immunotherapy (AIT) is the single disease-modifying treatment for allergy. Clinical trials show AIT to be safe and effective for many patients; however, it still faces problems related to efficacy, safety, long treatment duration and low patient adherence. There has been intensive...

Full description

Saved in:
Bibliographic Details
Published in:Allergo journal international 2018, Vol.27 (8), p.256-262
Main Authors: Benito-Villalvilla, Cristina, Soria, Irene, Subiza, José Luis, Palomares, Oscar
Format: Article
Language:English
Subjects:
Allergology
Clinical trials
Dendritic cells
Dermatology
Environmental Health
Immunology
Immunotherapy
Medicine
Medicine & Public Health
Review
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Allergen-specific immunotherapy (AIT) is the single disease-modifying treatment for allergy. Clinical trials show AIT to be safe and effective for many patients; however, it still faces problems related to efficacy, safety, long treatment duration and low patient adherence. There has been intensive research to develop alternative strategies, including novel administration routes, adjuvants or hypoallergenic molecules. Promising results are reported for some of them, but clinical progress is still moderate. Allergoids conjugated to nonoxidized mannan from  Saccharomyces cerevisiae  have emerged as a novel concept of vaccine targeting dendritic cells (DCs). Preclinical human and animal models demonstrated that allergoids conjugated to mannan enhance allergen uptake, promote healthy responses to allergens by inducing Th1 and T regulatory (Treg) cells, and show clinical efficacy in veterinary medicine. Dose-finding phase II clinical trials in humans are currently ongoing. We review the current stage of allergoids conjugated to mannan as next generation vaccines for AIT.
ISSN:2197-0378
2197-0378
DOI:10.1007/s40629-018-0069-8